Apellis Pharmaceuticals (APLS) News: Latest Stock Updates & Insights

Apellis Pharmaceuticals Overview

Apellis Pharmaceuticals, Inc. (Ticker: APLS) is a biopharmaceutical company focused on developing treatments for diseases with high unmet medical needs. The company innovates by targeting the complement system at the C3 level, an essential component of the immune system.

Key Products

• SYFOVRE® (pegcetacoplan injection): Approved for geographic atrophy (GA), a main cause of blindness related to age-related macular degeneration.
• EMPAVELI® (pegcetacoplan): Approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

Financial Performance

In 2023, Apellis generated $397 million in revenue, with significant contributions from SYFOVRE and EMPAVELI.

Recent Developments

Apellis achieved significant milestones in 2023:

• Presented positive data from the Phase 2 NOBLE study for systemic pegcetacoplan in treating rare kidney diseases at the European Renal Association Congress.
• Closed a $375 million funding deal with Sixth Street to buy out existing liabilities, boosting its liquidity and growth prospects.

Future Expectations

For 2024, Apellis expects:

• The European Medicines Agency (EMA) to review the marketing authorization application for SYFOVRE.
• Initial data from the Phase 3 VALIANT study of systemic pegcetacoplan in mid-2024.

Collaborations

Apellis collaborates with Sobi for the global co-development of systemic pegcetacoplan. The company balances scientific innovation with patient care, aiming to deliver life-changing therapies.

FAQs

1. What is the current stock price of Apellis Pharmaceuticals (APLS)?

   • The stock price is $33.93 as of November 29, 2024.

2. What is the market cap of Apellis Pharmaceuticals (APLS)?

   • The market cap is approximately $4.3 billion.

3. What does Apellis specialize in?

   • Apellis specializes in developing treatments for diseases with high unmet medical needs through complement system inhibition.

4. What are Apellis’s primary products?

   • The primary products are SYFOVRE® for geographic atrophy and EMPAVELI® for paroxysmal nocturnal hemoglobinuria.

5. How did Apellis perform financially in 2023?

   • Apellis generated $397 million in revenue in 2023.

6. What is SYFOVRE® approved for?

   • SYFOVRE® is approved for geographic atrophy (GA).

7. What is EMPAVELI® approved for?

   • EMPAVELI® is approved for paroxysmal nocturnal hemoglobinuria (PNH).

8. What recent clinical data has Apellis presented?

   • Positive data from the Phase 2 NOBLE study for systemic pegcetacoplan was presented.

9. What is the latest financial development for Apellis?

   • Apellis closed a $375 million funding deal to improve its liquidity profile.

10. What are Apellis’s expectations for 2024?

    • Apellis anticipates regulatory updates and topline data from the Phase 3 VALIANT study.

11. Who is Apellis collaborating with for systemic pegcetacoplan?

    • Apellis is collaborating with Sobi for global co-development.
12. How does Apellis combine science and patient care?
    • Apellis combines scientific research with caring for patients to deliver effective therapies.